{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T03:53:31Z","timestamp":1773546811062,"version":"3.50.1"},"reference-count":11,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,6]]},"abstract":"ABSTRACT<\/jats:title>\n \n Animal bite wounds affect more than 5 million Americans annually, resulting in 300,000 emergency department visits, 10,000 hospitalizations, and an untold number of physician office visits. Various forms of topical therapy are empirically self-employed by many patients prior to seeking medical attention. Pexiganan, a 22-amino-acid synthetic cationic analogue of the peptide magainin II, acts by selectively damaging bacterial cell membranes. We determined the MICs for pexiganan and other antimicrobial agents often used for treatment of bite wounds. Most isolates were from U.S. patients, and \u223c10% were from European and Canadian patients. The comparator antimicrobials studied were penicillin, amoxicillin-clavulanate, piperacillin-tazobactam, meropenem, clindamycin, doxycycline, moxifloxacin, ceftriaxone, linezolid, and metronidazole. The MIC\n 90<\/jats:sub>\n s of pexiganan were 32 \u03bcg\/ml (against\n Pasteurella multocida<\/jats:named-content>\n subsp.\n multocida<\/jats:named-content>\n ), 16 \u03bcg\/ml (\n P. multocida<\/jats:named-content>\n subsp.\n septica<\/jats:named-content>\n ,\n Pasteurella canis<\/jats:named-content>\n , and\n Pasteurella dagmatis<\/jats:named-content>\n ), 8 \u03bcg\/ml (\n Pasteurella stomatis<\/jats:named-content>\n ), 8 \u03bcg\/ml (\n Eikenella corrodens<\/jats:named-content>\n ), 2 \u03bcg\/ml (\n Neisseria weaveri<\/jats:named-content>\n ,\n Neisseria zoodegmatis<\/jats:named-content>\n , and\n Moraxella canis-Moraxella lacunata<\/jats:named-content>\n group), 16 \u03bcg\/ml (\n Bergeyella zoohelcum<\/jats:named-content>\n ), 64 \u03bcg\/ml (\n Bacteroides pyogenes<\/jats:named-content>\n ), 4 \u03bcg\/ml (\n Fusobacterium russii<\/jats:named-content>\n ), 32 \u03bcg\/ml (\n Fusobacterium canifelinum<\/jats:named-content>\n ), and 64 \u03bcg\/ml (\n Prevotella heparinolytica<\/jats:named-content>\n ). The concentration of pexiganan in the cream used was 8,000 \u03bcg\/ml, more than 60 to 100 times the highest MIC obtained. Pexiganan exhibited a broad range of antimicrobial activity, showing potential for treating animal bite infections. A clinical trial seems warranted.\n <\/jats:p>","DOI":"10.1128\/aac.00246-17","type":"journal-article","created":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T00:37:41Z","timestamp":1491266261000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["In Vitro<\/i>\n Activity of Pexiganan and 10 Comparator Antimicrobials against 234 Isolates, Including 93 Pasteurella Species and 50 Anaerobic Bacterial Isolates Recovered from Animal Bite Wounds"],"prefix":"10.1128","volume":"61","author":[{"given":"Ellie J. C.","family":"Goldstein","sequence":"first","affiliation":[{"name":"R. M. Alden Research Laboratory, Culver City, California, USA"},{"name":"David Geffen School of Medicine at UCLA, Los Angeles California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane M.","family":"Citron","sequence":"additional","affiliation":[{"name":"R. M. Alden Research Laboratory, Culver City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerin L.","family":"Tyrrell","sequence":"additional","affiliation":[{"name":"R. M. Alden Research Laboratory, Culver City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliza S.","family":"Leoncio","sequence":"additional","affiliation":[{"name":"R. M. Alden Research Laboratory, Culver City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00041-10"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0147-9571(93)90064-C"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-198701000-00008"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.8.6.667-672.1978"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901143400202"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.4.782"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1374"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/9781555817381"},{"key":"e_1_3_1_10_2","volume-title":"Wadsworth-KTL anaerobic bacteriology manual","author":"Jousimies-Somer HR","year":"2002","unstructured":"Jousimies-Somer HR SummanenPCitronDMBaronEJWexlerHMFinegoldSM. 2002. Wadsworth-KTL anaerobic bacteriology manual,6th ed. Star Publishing,Redwood City, CA.","edition":"6"},{"key":"e_1_3_1_11_2","volume-title":"Methods for antimicrobial dilution and disc susceptibility testing of infrequently isolated or fastidious bacteria; approved standard\u20143rd ed","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for antimicrobial dilution and disc susceptibility testing of infrequently isolated or fastidious bacteria; approved standard\u20143rd ed. CLSI M45-A3E. Clinical and Laboratory Standards Institute,Wayne, PA."},{"key":"e_1_3_1_12_2","volume-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard\u20148th ed","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard\u20148th ed. CLSI M11-A8. Clinical and Laboratory Standards Institute,Wayne, PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00246-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00246-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:38:22Z","timestamp":1645475902000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00246-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1128\/AAC.00246-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.00246-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"2017-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00246-17"}}